Updates

Explore Medicines360’s latest news and resources

Press Releases

New Survey Reveals Increasing Barriers for Women Seeking Birth Control and Disproportionate Impact on Women of Color

Faced with job losses and disruption from the pandemic, women find it more challenging in 2020 to access birth control, a critical aspect of women’s health San Francisco – November 18, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization fighting to make access to medicines for all women a reality, today released the […]

Read More >
Press Releases

Medicines360 Appoints Rolf Jansen as Vice President of Drug Development and Manufacturing

Jansen to Lead Product Expansion Focused on Essential Medicines Facing Access Challenges  SAN FRANCISCO – July 17, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Drug Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty years of pharmaceutical experience developing […]

Read More >
Press Releases

Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Reinforces Efficacy for Longest-Approved Duration of Use for a Hormonal IUS

SAN FRANCISCO – December 17, 2019 – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is highly efficacious in preventing pregnancy for up to six years of use. The publication also reports data related to the bleeding profile over the same period of […]

Read More >
Press Releases

FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

SAN FRANCISCO and DUBLIN – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing […]

Read More >
Press Releases

Medicines360 Launches #NotAwkward Campaign to Encourage Positive Conversations about Birth Control and Reproductive Health

New survey finds the top access challenge cited by women is feeling uncomfortable discussing sex or birth control SAN FRANCISCO (September 16, 2019)  – Medicines360, a nonprofit women’s health organization tackling the most pressing needs in women’s health, today announced the launch of #NotAwkward, a campaign to encourage positive conversations about birth control and reproductive […]

Read More >
Press Releases

Medicines360 Awarded “Clinical Trial Result of the Year” at 2019 CARE Awards

SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing […]

Read More >

FEATURED UPDATES

News

International Women’s Day at Direct Relief International

SANTA BARBARA INDEPENDENT – Direct Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >